About A/Prof Nada Hamad

A/Prof Nada Hamad is a senior staff specialist in bone marrow transplant, cellular therapies, clinical and laboratory haematologist at St Vincent’s hospital in Sydney, where she is also director of the haematology clinical trials unit. She is Chair of the ACI NSW BMT network and Chair of ALLG BMTCT working group. She also has a number of international leadership positions including membership of the WHO BMT quality taskforce. Dr Hamad studied Medicine at the University of Sydney and completed her Haematology training in Sydney. Prior to her career in medicine, she completed a Bachelor of Science and Master of Science in Forensics, working in this field for a short period of time. She completed two post-graduate fellowships in BMT and lymphoma at the Princess Margaret Cancer Centre in Toronto Canada through the University of Toronto. She has a strong interest in clinical trials and has a specialist certificate in Clinical Research (Oncology) from the University of Melbourne. Her clinical research interests are in malignant haematology and bone marrow transplantation. She is an intersectional feminist and a strong advocate for gender equity, diversity, and inclusion in medicine. She is the deputy chair of the gender equity, diversity, and inclusion in medicine committee at the University of NSW in Australia.

ANZTCT Position Statement: COVID-19 Management in Haematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T cell Patients 29 March 2022

Two years into the SARS-CoV-2 (COVID-19) pandemic, novel challenges continue to emerge. As the community moves towards high daily case numbers and circulating virus, or so called “COVID normal”, the risk for adult immunocompromised patients remains high. 1 In the paediatric setting data is lacking and the risks of morbidity and mortality are likely lower than in the adult setting.

In addition to the physical risk of COVID-19, there are additional psychosocial implications for patients who have received haematopoietic stem cell transplants and chimeric antigen receptor T cell therapies (TCT). Many patients report significant anxiety about COVID-19, and it is not always safe to isolate in the early post TCT period as patients recuperate at home post discharge.2 Another challenge in this cohort is prolonged post infection viral shedding, which can create challenges for access to medical care as well as other household members needing to isolate.

Transplant and cellular therapies are life-saving interventions and cannot routinely be postponed due to the risk of intervening disease relapse. This has forced great innovation and collaboration internationally by TCT clinicians to ensure access to safe and timely therapy against COVID-19 for TCT patients.

This position statement is intended to highlight relevant clinical issues unique to TCT patients and was developed in accordance with the ANZTCT policy for consensus practice/position statement development. The relevant literature has been reviewed and selected by the expert authors. The authorship group includes ANZTCT board members who have sought representatives from all TCT centres in Australia and New Zealand and key stakeholders including the Australasian Society of Infectious Diseases, the Haematology Society of Australia and New Zealand, the Australian and New Zealand Bone Marrow Donor Registries, Leukaemia foundation and Leukaemia and Blood Cancer New Zealand. The ANZTCT is committed to equity, diversity and inclusion so geographic representation, gender balance and diversity of backgrounds and disciplines was considered where possible.

Read the full position statement here

This position statement will be regularly reviewed and updated as further data on COVID-19 therapeutics emerge.

ANZTCT COVID-19 Vaccination Position Statement

Australia and New Zealand Transplant and Cellular Therapies COVID-19 Vaccination Consensus Position Statement 20th January 2021

Australia and New Zealand have achieved very good control of the community spread of SARS-CoV-2 during the global pandemic due to highly effective public health interventions (1-2). Amongst autologous and allogeneic haematopoietic stem cell transplant and CAR-T cell (TCT) patients, there has been 1 death and <5 infections reported to date.

Haematology patients including bone marrow transplant patients are at high risk of complications and death from COVID-19 with an estimated mortality of up to 36%, which is comparable to the mortality rate of aged care residents (3-5). While mortality risk in paediatric patients (estimated at 4%) is lower, it is much higher than in healthy children (4). The rates of severe disease requiring ventilation is estimated at 15% and 13% in allogeneic and stem cell transplant recipients respectively. Factors associated with a higher risk of mortality include age >50 years; male sex and development of COVID-19 within 12 months of transplantation (5). Furthermore, preliminary reports suggest that immunocompromised haematology patients have prolonged virus shedding and the potential for accelerated viral evolution (6-8). These data should inform future preventative efforts as both countries commence their vaccination campaigns.

At the time of writing, there are two vaccines of relevance in Australia and New Zealand. The Pfizer/BioNTech SARS-Cov-2 vaccine is a first-in-class mRNA vaccine which in an international phase 3 study was administered to 43,448 participants aged 16 or older in a two dose regimen 21 days apart. The vaccine was 95% effective against symptomatic COVID-19 from seven days after the second dose. Efficacy was consistent across age, gender and ethnicity, and no serious safety concerns were reported. This trial included a small number of patients (n=76) with leukaemia or lymphoma as a co-morbidity, 36 of whom received the vaccine (9). The AstraZeneca ChAdOx1 nCOV-19 vaccine is a replication-deficient chimpanzee adenoviral vectored vaccine given in a two dose regimen. In a pooled analysis across four studies with varying dosing, overall vaccine efficacy was 70.4% with no serious safety concerns reported (10). In a subgroup of 8,895 participants who received two standard doses (as will be administered in practice), vaccine efficacy was 62%. Experience with viral vectored vaccines is limited with no evidence in haematology or TCT patients. An alternative vaccine available internationally is the Moderna mRNA SARS-CoV-2 vaccine (mRNA-1273) which is another two dose regimen vaccine administered 28 days apart, shown in a phase 3 study to have an overall efficacy of 94% (11). Other vaccines with potential future relevance in Australia and New Zealand include the Novovax vaccine NVX-CoV2373, the Janssen vaccine Ad26Cov2S and access to the COVAX facility.

None of these studies included immunocompromised participants or TCT patients. There are currently no studies specifically evaluating vaccine response or efficacy in TCT patients. Despite the lack of data, none of these is a live vaccine and therefore none poses a risk of COVID-19 transmission. While there is no specific data on patients with graft versus host disease, other vaccine products have not shown a risk of worsening acute or chronic graft versus host disease (12).

Given this paucity of data, representatives of all adult and paediatric allogeneic bone marrow transplant centres and cellular therapy centres as well as  representatives from autologous only centres in Australia and New Zealand collaborated with Infectious Disease specialists with expertise in TCT on this consensus position statement regarding COVID-19 vaccination in TCT patients in Australia and New Zealand:

  1. Given the high mortality risk associated with COVID-19 in TCT patients, TCT patients and health care workers delivering care to these patients should be prioritised (13).
  2. The benefits of vaccination outweigh the unknowns in TCT patients without contraindications such as allergies to the vaccine.
  3. Patients planned for TCT should be vaccinated as soon as feasible prior to TCT without deferral of TCT.
  4. Where possible, vaccination should be completed at least two weeks before planned TCT procedures (14).
  5. It is acknowledged that optimal responses to the vaccine are more likely >6 months post TCT and when patients are off immunosuppressive therapy. Clinicians could consider vaccination as early as 3-6 months post-TCT in patients aged ≥ 16 depending on local and community transmission and clinical factors (13, 15).
  6. The unknown risks in the setting of graft versus host disease (GVHD) are likely to be outweighed by the benefits, particularly in patients with lung GVHD. Therefore, in allogeneic HSCT recipients who remain on immunosuppressive therapy beyond 6 months, consideration should be given to the indication, intensity and expected duration of immunosuppressive therapy when deciding whether to vaccinate or defer. Especially if patients are close to weaning off immune suppressive therapy, a short period of deferral may improve immunogenicity to vaccination and would be appropriate in the context of well controlled community transmission (13,15).
  7. TCT patients should be advised to continue to practice usual public health measures (e.g. masks, physical distancing, avoiding crowds, ensuring good indoor ventilation, and hand hygiene) in accordance with national and regional guidelines after vaccination as immunogenicity and efficacy in these patients is unknown (15).
  8. Patients with suspected or confirmed previous COVID-19 infection should be vaccinated as per international guidelines as immunity may wane (16 -17).
  9. Available vaccines are not licensed for use in patients under the age of 16 years noting that trials are underway to answer this question (15).
  10. Healthy bone marrow transplant donors should be vaccinated as soon as possible prior to donation, preferably within 3 months prior to donation without deferral of donation.
  11. Household transmission is one of the most common mechanisms of SARS-CoV-2 transmission. Therefore, vaccination of household members and/or carers of haematology patients, with high efficacy vaccines should be prioritised (18).
  12. Acknowledging the lack of data for efficacy and safety of COVID-19 vaccines in TCT patients, we recommend highly efficacious mRNA vaccines in TCT patients, health care workers delivering their care, and household members. This preference, however, should not delay vaccination with more immediately available vaccines.
  13. Where feasible, assessment of vaccine response with post-vaccination serology testing should be performed in TCT patients.
  14. Studies to determine the optimal vaccine, timing, the number of doses and schedule in TCT patients are urgently needed. It is also important to consider the role of donor vaccination and the role of vaccination in paediatric TCT patients since this cohort was excluded from the pivotal above mentioned studies.

These statements will be regularly reviewed and updated as further data on vaccines emerge. Updates will be made on the ANZTCT website www.anztct.org.au.

ANZTCT COVID-19 Vaccination Position Statement, 20th January 2021


  1. Coronovirus Government Response Tracker [Available from: https://www.bsg.ox.ac.uk/research/research-projects/coronavirus-government-response-tracker.
  2. Robert A. Lessons from New Zealand’s COVID-19 outbreak response. Lancet Public Health. 2020;5(11):e569-e70.
  3. De Ramón C, Hernandez-Rivas JA, Rodríguez García JA, Ocio EM, Gómez-Casares MT, López Jiménez J, et al. Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study. Blood. 2020;136(Supplement 1):5-6.
  4. Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881-92.
  5. Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. The Lancet Haematology. 2021.
  6. Abdul-Jawad S, Baù L, Alaguthurai T, del Molino del Barrio I, Laing AG, Hayday TS, et al. Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients. Cancer Cell.
  7. Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell. 2020;183(7):1901-12.e9.
  8. Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med. 2020;383(23):2291-3.
  9. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.
  10. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.
  11. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020.
  12. Per Ljungman SC, Catherine Cordonnier, Malgorzata Mikulska, Jan Styczynski, Rafael de la Camara. COVID-19 vaccines. Version 2.0 December 21, 2020 [Available from: https://www.ebmt.org/sites/default/files/2020-12/COVID%20vaccines%20version%202.03%20with%20table.pdf.
  13. Paulson K. Cell Therapy Transplant Canada Position Statement on COVID-19 Vaccination.
  14. COVID-19 Vaccine in patients with haematological disorders British Society for Haematology [updated 21st December 2020. Available from: https://b-s-h.org.uk/media/19195/haematology-covid-19-v10-vaccination-statement-231220.pdf.
  15. SARS-CoV-2 vaccination following haematopoietic stem cell transplant (HSCT) and chimeric antigen receptor T-cell (CAR-T) therapy. Prepared by the British Society of Blood and Marrow Transplantation and Cellular Therapy Vaccination Sub-Committee (BSBMTCT-VSC) 2021 [updated 12 January 2021. Available from: https://bsbmtct.org/wp-content/uploads/2020/12/BSBMTCT-COVID-19-Guidelines-5.0-Dec-2020_final.pdf.
  16. Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States [Available from: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html.
  17. Input from Drs. Jeff Auletta RC, Fareed Khawaja, Genovefa Papanicolaou, Josh Hill, Julie Kanter, Alpana Waghmare, Adrian Wiestner, John Wingard. ASH-ASTCT COVID-19 and Vaccines: Frequently Asked Questions [updated Version 2.1; last updated December 23, 2020. Available from: https://www.hematology.org/covid-19/ash-astct-covid-19-and-vaccines.
  18. Brockhoff R, Akan H, Duarte R, Honigl M, Klimko N, Mellinghoff SC, et al. Recommendations for COVID-19 vaccination in patients with hematologic cancer: European Hematology Association; 2021 [Available from: https://ehaweb.org/covid-19/eha-statement-on-covid-19-vaccines/recommendations-for-covid-19-vaccination-in-patients-with-hematologic-cancer/.

Other resources: 

Authors and Affiliations:

Nada Hamad: St Vincent’s Hospital Sydney and University of New South Wales

Michelle Ananda-Rajah: Monash Institute of Medical Engineering and Alfred Health

Nicole Gilroy: Centre for Infectious Diseases and Microbiology, Westmead Hospital

Raina MacIntyre: Kirby Institute and University of New South Wales

David Gottlieb: University of Sydney and Westmead Hospital

David Ritchie: Clinical Haematology, Peter MacCallum Cancer Centre & The Royal Melbourne Hospital

Simon Harrison: Clinical Haematology, Peter MacCallum Cancer Centre & The Royal Melbourne Hospital

Glen Kennedy: Royal Brisbane and Women’s Hospital

Anne Marie Watson: Liverpool Hospital

Matthew Greenwood: Royal North Shore Hospital

Richard Doocey: Auckland City Hospital

Travis Perera: Wellington Blood and Cancer Centre

Andrew Spencer: The Alfred Hospital and Monash University

Eric Wong: Austin Hospital

Tracey O’Brien: Sydney Children’s Hospital

Peter Shaw: University of Sydney and Westmead Hospital

Rachel Conyers: The Royal Children’s Hospital

Sam Milliken: St Vincent’s Hospital Sydney

Peter Bardy: Royal Adelaide Hospital

Phoebe Joy Ho: Royal Prince Alfred Hospital and the University of Sydney

Stephen Larsen: Royal Prince Alfred Hospital and the University of Sydney

Hock Lai: Townsville Hospital

Ashish Bajel: Clinical Haematology, Peter MacCallum Cancer Centre & The Royal Melbourne Hospital

Jason Butler: Royal Brisbane and Women’s Hospital

Campbell Tiley: Gosford Hospital and University of Newcastle

James D’Rozario: Canberra Hospital

Anna Johnston: Royal Hobart Hospital

Tara Cochrane: Gold Coast University Hospital

Tony Mills: Princess Alexandria Hospital

Ian Irving: ICON Cancer Centre

Humprey Pullon: Waikato Hospital

Duncan Purtill: Fiona Stanley Hospital

Australia and New Zealand Transplant and Cellular Therapies COVID19 Consensus Position Statement 15th April 2020

In the context of a viral pandemic, utilisation of health care resources may exceed standard capacity. The impact of potential resource limitation on the needs of a stem cell transplant and bone marrow service needs to be carefully considered. Challenges are likely to include reduced availability of highly specialised health care staff due to illness or allocation to other areas, as well as compromised infrastructure and acute care bed capacity.

Representatives of all adult and paediatric allogeneic stem cell transplant centres in Australia and New Zealand have been in regular communication and have collectively come to a consensus regarding several issues relating to the COVID-19 pandemic:

  1. Centres will identify backup donor options for patients undergoing allogeneic transplant from interstate and overseas unrelated donors, including haploidentical related donors and cord blood donors. Travel restrictions and illness are likely to reduce the unrelated donor pool.
  2. Centres will cryopreserve all international and possibly interstate unrelated donor products before starting conditioning. Cryopreservation by the collecting centre will be requested as a preference for international donors.
  3. Donors who have developed COVID-19 will be excluded for at least three months. Refer to updated international guidelines for the management of donors with contact or geographical risk of SARS-CoV-2 exposure (1-3).
  4. The ABMDR will update donor questionnaires to include questions specific to risk factors for COVID-19.
  5. Donors and recipients should be screened for symptoms of COVID-19 prior to commencement of donor mobilisation and recipient conditioning. Routine donor screening is recommended if feasible, although the sensititivy of screening in asymptomatic donors, and optimal timing of this testing, remains uncertain.
  6. Centres should attempt to triage transplants. Triage will depend on patient, donor and disease factors. This should include consideration of risks of disease progression or relapse and estimated transplant related mortality. It is not possible to develop a strict triage protocol that would take into account all eventualities or how the COVID-19 pandemic will evolve. Nevertheless, general suggestions for disease-based triage are as follows:
    • High priority: Adverse outcomes are expected if transplant is delayed for any reason other than patient factors.
      • Allogeneic transplantation
        • Acute leukaemia with considerations for the DRI and HCTCI
        • High risk myelodysplastic syndrome not responding to bridging therapy
        • Aplastic anaemia
        • Severe combined immune deficiency in children
      • Autologous transplantation
        • Relapsed/refractory aggressive lymphoma or Hodgkin lymphoma
        • CNS lymphoma in first remission based on individual patient considerations
        • Multiple myeloma failing induction therapy
    • Intermediate priority: Patients can be delayed with bridging therapies used where possible to stabilise disease while awaiting transplant.
      • Allogeneic transplantation
        • Stable myelodysplastic syndrome
        • Stable myelofibrosis
      • Autologous transplantation
        • Multiple myeloma with consideration of collection of autologous cells based on local resources
        • Relapsed indolent lymphoma
        • MCL in first remission
        • Highgrade lymphoma in first remission
    • Low priority: Patients can be delayed with low risk of adverse outcome
      • Allogeneic transplantation
        • CML in chronic phase
        • Low grade lymphoproliferative disorders including CLL and indolent lymphoma
        • Sickle cell disease
        • Immunodeficiency
      • Autologous transplantation
        • Autoimmune diseases (multiple sclerosis, myasthenia gravis, systemic sclerosis)
        • Amyloidosis
        • Clinical trials: unless the clinical trial provides standard of care transplantation that patients would otherwise receive.


  1. WMDA: share.wmda.info, accessed 27 March 2020
  2. ASTCT: Interim Guidelines for COVID-19 Management in Hematopoietic Cell Transplant and Cellular Therapy Patients Version 1.1, March 9 2020 available at https://higherlogicdownload.s3.amazonaws.com/ASBMT/a1e2ac9a-36d2-4e23-945c-45118b667268/UploadedImages/COVID-19_Interim_Patient_Guidelines_3_9_20_V2.pdf, accessed 14 March 2020
  3. EBMT: ‘CORONAVIRUS DISEASE COVID-19: Updated EBMT Recommendations (8thMarch 2020)’ available at https://www.ebmt.org/sites/default/files/2020-03/EBMT%20COVID-19%20guidelines%20v.2%20%282020-03- 10%29.pdf, accessed 14 March 2020

Authors and Affiliations:

  • Nada Hamad: St Vincent’s Hospital Sydney and University of New South Wales
  • David Gottlieb: University of Sydney and Westmead Hospital
  • David Ritchie: Clinical Haematology, Peter MacCallum Cancer Centre & The Royal Melbourne HospItal Glen Kennedy: Royal Brisbane and Women’s Hospital
  • Anne Marrie Watson: Liverpool Hospital
  • Matthew Greenwood: Royal North Shore Hospital
  • Richard Doocey: Auckland City Hospital
  • Travis Perera: Wellington Blood and Cancer Centre
  • Andrew Spencer: The Alfred Hospital and Monash University
  • Eric Wong: Austin Hospital
  • Tracey O’Brien: Sydney Children’s Hospital
  • Peter Shaw: University of Sydney and Westmead Hospital
  • Rachel Conyers: The Royal Children’s Hospital
  • Theresa Cole: The Royal Children’s Hospital
  • Sam Milliken: St Vincent’s Hospital Sydney
  • Peter Bardy: Royal Adelaide Hospital
  • Stephen Larsen: Royal Prince Alfred Hospital and the University of Sydney
  • Hock Lai: Townsville Hospital
  • Andrew Butler: Christchurch Hospital
  • Chris Fraser: Queensland Children’s Hospital
  • Ashish Bajel: Clinical Haematology, Peter MacCallum Cancer Centre & The Royal Melbourne HospItal Jason Butler: Royal Brisbane and Women’s Hospital
  • Ian Kerridge: Royal North Shore Hospital and the University of Sydney
  • Duncan Purtill: Fiona Stanley Hospital

ANZTCT COVID19 Position Statement